Thrombolytic therapy during cardiopulmonary resuscitation is not routinely recommended, but 50-70% of cardiac arrests are caused by either acute myocardial infarction or massive pulmonary embolism. Thrombolytic therapy can be a reasonable treatment modality for a patient suffering with cardiac arrest in an emergency situation and whose diagnosis is not known. We report here on a case with cardiac arrest and the diagnosis was not known. The patient was refractory to conventrional cardiopulmonary resuscitation, and he was treated with a bolus injection of a thrombolytic agent. He recovered completely without complications. 
Introduction
The prognosis of cardiac arrest is generally poor. Many studies have shown survival rates ranging from 0% to 20.7% and approximately 95% patients with out-ofhospital cardiac arrest die or have irreversible neurologic impairment. [1] [2] [3] [4] Fifty to 70% of cardiac arrests in westurn countries are caused either by acute myocardial infarction or massive pulmonary embolism 5) but thrombolytic therapy is not routinely recommended due to the fear of massive hemorrhage.
We present here a case with cardiac arrest and the initial diagnosis was not known. The patient was refractory to conventional cardiopulmonary resuscitation, and he successfully treated with a bolus injection of a thrombolytic agent.
Case
A 43 year old man was admitted to the emergency room because of loss of consciousness. A witness said that he had felt severe anterior chest pain 1 hour before and he suddenly lost consciousness in a taxi 5 minutes prior to admission.
His vital signs on arrival were catastrophic. Zero mmHg of blood pressure (BP), no self respiration, fully dilated both pupils, asystole and a comatose mentality were all noticed. The electrocardiogram (ECG) showed no electrical activity (Fig. 1A) . Advanced cardiac life support was immediately implemented, including intubation and external chest compression. Ventricular fibrillation developed (Fig. 1B) and he received four attempts at defibrillation with administering atropine, epinephrine, sodium bicarbonate and lidocaine. His rhythm was changed to pulseless electrical activity and he was without spontaneous circulation for 25 minutes. The patient was given bolus tenecteplase 40 mg IV during the period of pulseless electrical activity (Fig. 1C) . Spontaneous circulation returned 45 minutes after administering IV tenecteplase along with with cardiopulmonary resuscitation, and the BP of the patient was 120/90 mmHg (Fig. 1D ). Yet his mentality was still stuporous, and the Babinski and ankle clonus signs were positive. The supportive care was continued with all possible measures, including ventilator therapy. After 8 hours, his mentality was improved to a drowsy state and the Babinski and ankle clonus signs turned negative. Considering the definite Q waves in the precordial leads (V1 to V4) and the stabilized vital signs, we chose conservative treatment and we delayed performing percutaneous coronary intervention.
One day after IV tenecteplase, his mental status became alert and the vital sign were stable in the cardiac care unit. The echocardiogram showed a LVEF of 42%, regional wall motion abnormality in the anterior wall and a normal left ventricular dimension. Coronary angiography was performed and the proximal left anterior descending artery showed a critical area of stenosis and so a sirolimus eluting stent was implanted. He was discharged and has been followed up regularly without events or complications for over 1 year.
Discussion
The recent guidelines by the American College of Cardiology (ACC) and the American Heart Association (AHA) state that thrombolytic therapy during cardiopulmonary resuscitation is no longer contraindicated. 6) In certain circumstances, thrombolysis during cardiopulmonary resuscitation does not result in fundamental bleeding complications, but it is feasible, safe and effective.
Cardiac arrest and cardiopulmonary resuscitation (CPR) lead to striking activation of blood coagulation, yet this is without adequate activation of endogenous fibrinolysis and it induces microthromboses throughout the entire microcirculation. 7) 8) The thrombolytic agents can treat certain causes of cardiac arrest during symptomatic treatment (CPR) and they also have an effect on microcirculatory reperfusion after cardiac arrest, and especially during cerebral and end organ reperfusion.
3)7)
Beyond the direct effects on pulmonary or cardiac vessel thrombosis, thrombolytics may offer neuroprotective and end organ benefits for patients in cardiac arrest. In a feline model of circulatory arrest, microvascular thrombi can be a major factor for a poor neurologic outcome during and after cardiac arrest, but in the thrombolytic group, improved flow in the cerebral cortex resulted in a significant reduction of no reflow and improved perfusion. 9) No reflow is also directly related to microvascular thrombosis, so it can be successfully prevented and treated with thrombolytics. 10)11) From this point of view, thrombolytics therapy itself has many benefits for thrombo-occlusive events as a mediator of arrest. Patients in cardiac arrest from other causes may have little or nothing to lose when receiving the possible neuroprotective and end organ perfusion effects of thrombolysis during arrest.
The side effects of thrombolytic therapy include intracranial hemorrhage, systemic hemorrhage, immunologic reactions, hypotension and reperfusion injury. There is a 0.95% incidence of intracranial hemorrhage, a 0.7% incidence of bleeding complication and a 1.65% incidence of total side effects. 12) So, great risk benefits exist between the 2% risk of complications and 95% risk of death or permanent major neurologic impairment. The recent international recommendations no longer regard CPR as a contraindication for thrombolysis, 6)13) and only a small fraction of patients would be affected by the unique thrombolytic effects or immunologic complications and the majority of these would experience no permanent morbidity.
On a recent meta-analysis, thrombolytic therapy signigicantly improved the rate of return of spontaneous circulation, the 24 hour survival rate, the rate of survival to discharge, the long term neurological function and the degree of bleeding. 14) In conclusion, thrombolytic therapy during CPR has an effect on thrombo-occlusive events like acute myocardial infarction and massive pulmonary embolism as a mediator of arrest and it also may improve microcirculatory perfusion, especially in the brain and other end organs. The potential risks during thrombolytic therapy do not overweigh the benefits in the setting of cardiac arrest. Yet the studies on thrombolytic therapy during or after CPR have been scattered and retrospective in nature. Therefore, large randomized multicenter trials will be needed for assessing the efficacy and safety of the prehospital use of thrombolytics during CPR.
